Thanks for responding Stweeve and Anyones Guess. My last post got cut off on the right-hand-side losing some of it's meaning. I will have to write shorter lines!
Here are three more quotes from 20 Feb 14 Investor Presentation.
•40 sites in Australia used for “in market” product development, commercialisation and early sales
•US Distribution commencing by Medline in Q1 14 (Medline have 1100 sales reps and 37 distribution centres and we are now in Q1 2014)
•Global distribution discussions advancing in Canada and the EU
It's a commercialised product with FDA clearance, a strong patent and no competition.
Wouldn't this indicate early market acceptance in Australia? Would Medline take the product on if they weren't sure there was a ready market in the US?
I took a small position this morning. I see this as a buy and hold stock which can get a rocket underneath it as news of US, Canada and EU sales start to come through.
I had first-hand experience with the whole incontinence issue whilst caring for my father-in-law most of last year before his death in December. It's an enormous problem in hospitals and nursing homes and Simavita have a solution.
SVA Price at posting:
73.0¢ Sentiment: LT Buy Disclosure: Held